BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.
“Clinical and Virologic Outcomes with Peramivir Therapy in Hospitalized Adults with Influenza B: Sub-Group Analysis of a Phase 2 Trial”
The data will be presented during a poster session scheduled for Friday, October 22, 2010 from 12:30-2:00 p.m. Eastern Time. The two posters to be presented during the session include:
•Presentation Number 761: “Clinical and Virologic Outcomes with Peramivir Therapy in Hospitalized Adults with Influenza B: Sub-Group Analysis of a Phase 2 Trial,” which concludes that peramivir and oseltamivir treatment resulted in similar clinical outcomes in the overall study population>
•Presentation Number 765: “Neutropenia Is Not Related to Neuraminidase Inhibitor (NAI) Therapy of Uncomplicated Influenza in Phase 2 and 3 Controlled Clinical Trials,” which describes the effects of influenza infection on lymphocyte and neutrophil populations and concludes that in placebo- or oseltamivir-controlled trials, peramivir has no apparent effects on leukocyte counts or risk of neutropenia in patients with influenza. Results were drawn from an analysis of data from five Phase 2 and Phase 3 clinical trials which included over 2,200 influenza patients treated with peramivir or a control.
Source:BioCryst Pharmaceuticals, Inc.